Trade Treace Medical Concepts, Inc. - TMCI CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Spread | 0.08 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Treace Medical Concepts Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 12.34 |
Open* | 12.47 |
1-Year Change* | -49.68% |
Day's Range* | 12.44 - 13.11 |
52 wk Range | 5.27-27.97 |
Average Volume (10 days) | 915.26K |
Average Volume (3 months) | 22.09M |
Market Cap | 783.28M |
P/E Ratio | -100.00K |
Shares Outstanding | 61.68M |
Revenue | 174.68M |
EPS | -0.79 |
Dividend (Yield %) | N/A |
Beta | -100.00K |
Next Earnings Date | Feb 27, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Mar 27, 2024 | 12.34 | 0.81 | 7.03% | 11.53 | 12.39 | 11.49 |
Mar 26, 2024 | 11.45 | -0.29 | -2.47% | 11.74 | 11.86 | 11.41 |
Mar 25, 2024 | 11.81 | -0.34 | -2.80% | 12.15 | 12.25 | 11.79 |
Mar 22, 2024 | 12.14 | -0.05 | -0.41% | 12.19 | 12.52 | 11.96 |
Mar 21, 2024 | 12.53 | -0.03 | -0.24% | 12.56 | 12.79 | 12.49 |
Mar 20, 2024 | 12.47 | 0.41 | 3.40% | 12.06 | 12.63 | 11.99 |
Mar 19, 2024 | 12.11 | 0.46 | 3.95% | 11.65 | 12.22 | 11.65 |
Mar 18, 2024 | 11.98 | 0.05 | 0.42% | 11.93 | 12.27 | 11.56 |
Mar 15, 2024 | 11.86 | 0.07 | 0.59% | 11.79 | 12.26 | 11.72 |
Mar 14, 2024 | 12.17 | -0.13 | -1.06% | 12.30 | 12.30 | 11.65 |
Mar 13, 2024 | 12.28 | 0.10 | 0.82% | 12.18 | 12.48 | 12.18 |
Mar 12, 2024 | 12.33 | -0.41 | -3.22% | 12.74 | 12.74 | 12.33 |
Mar 11, 2024 | 12.79 | -0.08 | -0.62% | 12.87 | 13.10 | 12.63 |
Mar 8, 2024 | 13.10 | -0.14 | -1.06% | 13.24 | 13.65 | 12.97 |
Mar 7, 2024 | 13.22 | -0.04 | -0.30% | 13.26 | 13.72 | 13.20 |
Mar 6, 2024 | 13.23 | 0.12 | 0.92% | 13.11 | 13.28 | 12.97 |
Mar 5, 2024 | 13.11 | -0.37 | -2.74% | 13.48 | 13.66 | 13.11 |
Mar 4, 2024 | 13.69 | 0.41 | 3.09% | 13.28 | 13.76 | 13.12 |
Mar 1, 2024 | 13.37 | 0.20 | 1.52% | 13.17 | 13.71 | 13.16 |
Feb 29, 2024 | 13.39 | -0.14 | -1.03% | 13.53 | 13.94 | 13.19 |
Treace Medical Concepts, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Monday, May 6, 2024 | ||
Time (UTC) 10:59 | Country US
| Event Q1 2024 Treace Medical Concepts Inc Earnings Release Q1 2024 Treace Medical Concepts Inc Earnings ReleaseForecast -Previous - |
Wednesday, May 22, 2024 | ||
Time (UTC) 15:00 | Country US
| Event Treace Medical Concepts Inc Annual Shareholders Meeting Treace Medical Concepts Inc Annual Shareholders MeetingForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | |
---|---|---|---|---|
Total revenue | 141.838 | 94.419 | 57.365 | 39.416 |
Revenue | 141.838 | 94.419 | 57.365 | 39.416 |
Cost of Revenue, Total | 27.523 | 17.826 | 12.47 | 7.631 |
Gross Profit | 114.315 | 76.593 | 44.895 | 31.785 |
Total Operating Expense | 181.465 | 110.929 | 56.51 | 42.951 |
Selling/General/Admin. Expenses, Total | 135.575 | 82.899 | 38.193 | 30.25 |
Research & Development | 13.584 | 10.204 | 5.847 | 5.07 |
Operating Income | -39.627 | -16.51 | 0.855 | -3.535 |
Interest Income (Expense), Net Non-Operating | -3.188 | -4.042 | -4.523 | -0.73 |
Net Income Before Taxes | -42.815 | -20.552 | -3.668 | -4.265 |
Net Income After Taxes | -42.815 | -20.552 | -3.668 | -4.265 |
Net Income Before Extra. Items | -42.815 | -20.552 | -3.668 | -4.265 |
Net Income | -42.815 | -20.552 | -3.668 | -4.265 |
Total Adjustments to Net Income | 0 | -0.196 | -0.64 | -0.64 |
Income Available to Common Excl. Extra. Items | -42.815 | -20.748 | -4.308 | -4.905 |
Income Available to Common Incl. Extra. Items | -42.815 | -20.748 | -4.308 | -4.905 |
Diluted Net Income | -42.815 | -20.748 | -4.308 | -4.905 |
Diluted Weighted Average Shares | 55.2768 | 48.4157 | 50.4628 | 50.4628 |
Diluted EPS Excluding Extraordinary Items | -0.77456 | -0.42854 | -0.08537 | -0.0972 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | ||
Diluted Normalized EPS | -0.68803 | -0.42854 | -0.08537 | -0.0972 |
Unusual Expense (Income) | 4.783 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 41.953 | 42.195 | 49.769 | 33.055 | 29.967 |
Revenue | 41.953 | 42.195 | 49.769 | 33.055 | 29.967 |
Cost of Revenue, Total | 7.675 | 8.039 | 9.742 | 6.624 | 5.291 |
Gross Profit | 34.278 | 34.156 | 40.027 | 26.431 | 24.676 |
Total Operating Expense | 55.005 | 55.971 | 53.566 | 44.373 | 46.383 |
Selling/General/Admin. Expenses, Total | 43.804 | 44.52 | 39.775 | 33.95 | 33.625 |
Research & Development | 3.526 | 3.412 | 3.749 | 3.799 | 2.984 |
Operating Income | -13.052 | -13.776 | -3.797 | -11.318 | -16.416 |
Interest Income (Expense), Net Non-Operating | 0.686 | 0.194 | -0.615 | -0.815 | -0.815 |
Net Income Before Taxes | -12.271 | -13.454 | -4.412 | -12.133 | -17.234 |
Net Income After Taxes | -12.271 | -13.454 | -4.412 | -12.133 | -17.234 |
Net Income Before Extra. Items | -12.271 | -13.454 | -4.412 | -12.133 | -17.234 |
Net Income | -12.271 | -13.454 | -4.412 | -12.133 | -17.234 |
Total Adjustments to Net Income | 0 | 0 | |||
Income Available to Common Excl. Extra. Items | -12.271 | -13.454 | -4.412 | -12.133 | -17.234 |
Income Available to Common Incl. Extra. Items | -12.271 | -13.454 | -4.412 | -12.133 | -17.234 |
Diluted Net Income | -12.271 | -13.454 | -4.412 | -12.133 | -17.234 |
Diluted Weighted Average Shares | 61.3825 | 58.7238 | 55.5356 | 55.4292 | 55.3083 |
Diluted EPS Excluding Extraordinary Items | -0.19991 | -0.22911 | -0.07944 | -0.21889 | -0.3116 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.19991 | -0.22911 | -0.07404 | -0.21889 | -0.23054 |
Unusual Expense (Income) | 0 | 0.3 | 0 | 4.483 | |
Other, Net | 0.095 | 0.128 | -0.003 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | |
---|---|---|---|---|
Total Current Assets | 133.402 | 137.972 | 40.978 | 28.57 |
Cash and Short Term Investments | 81.252 | 105.833 | 18.079 | 12.139 |
Cash & Equivalents | 16.211 | 105.833 | 18.079 | 12.139 |
Total Receivables, Net | 29.196 | 18.568 | 14.486 | 10.411 |
Accounts Receivable - Trade, Net | 29.196 | 18.568 | 14.486 | 10.411 |
Total Inventory | 19.33 | 10.561 | 7.82 | 5.562 |
Prepaid Expenses | 3.624 | 3.01 | 0.594 | 0.458 |
Total Assets | 159.024 | 140.821 | 41.807 | 29.716 |
Property/Plant/Equipment, Total - Net | 25.476 | 2.849 | 0.829 | 1.146 |
Property/Plant/Equipment, Total - Gross | 29.739 | 5.588 | 3.465 | 2.787 |
Accumulated Depreciation, Total | -4.263 | -2.739 | -2.636 | -1.641 |
Total Current Liabilities | 30.245 | 18.21 | 11.598 | 7.332 |
Accounts Payable | 8.668 | 4.056 | 2.265 | 0.931 |
Accrued Expenses | 21.577 | 14.154 | 7.544 | 6.401 |
Notes Payable/Short Term Debt | 0 | 0 | 1.788 | 0 |
Total Liabilities | 98.495 | 47.748 | 41.031 | 26.555 |
Total Long Term Debt | 52.711 | 29.365 | 29.189 | 19.223 |
Long Term Debt | 52.711 | 29.365 | 29.189 | 19.223 |
Other Liabilities, Total | 15.539 | 0.173 | 0.244 | 0 |
Total Equity | 60.529 | 93.073 | 0.776 | 3.161 |
Redeemable Preferred Stock | 0 | 0 | 7.935 | 7.935 |
Common Stock | 0.055 | 0.045 | 0.028 | 0.028 |
Additional Paid-In Capital | 145.221 | 134.933 | 14.166 | 12.884 |
Retained Earnings (Accumulated Deficit) | -84.72 | -41.905 | -21.353 | -17.686 |
Total Liabilities & Shareholders’ Equity | 159.024 | 140.821 | 41.807 | 29.716 |
Total Common Shares Outstanding | 55.6282 | 54.1811 | 50.4628 | 50.4628 |
Other Current Assets, Total | -0.001 | |||
Other Current Liabilities, Total | 0.001 | |||
Cash | 3.262 | |||
Short Term Investments | 61.779 | |||
Other Long Term Assets, Total | 0.146 | |||
Other Equity, Total | -0.027 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 187.142 | 198.096 | 223.133 | 133.402 | 127.902 |
Cash and Short Term Investments | 122.163 | 139.479 | 170.662 | 81.252 | 88.546 |
Cash & Equivalents | 2.738 | 9.084 | 26.147 | 16.211 | 85.839 |
Total Receivables, Net | 24.996 | 27.232 | 25.365 | 29.196 | 18.548 |
Accounts Receivable - Trade, Net | 24.996 | 27.232 | 25.365 | 29.196 | 18.548 |
Total Inventory | 29.312 | 26.101 | 22.519 | 19.33 | 16.794 |
Prepaid Expenses | 10.671 | 5.284 | 4.587 | 3.624 | 4.014 |
Total Assets | 240.36 | 249.643 | 249.17 | 159.024 | 156.443 |
Property/Plant/Equipment, Total - Net | 30.995 | 29.086 | 25.822 | 25.476 | 28.395 |
Property/Plant/Equipment, Total - Gross | 38.225 | 35.08 | 30.898 | 29.739 | 31.926 |
Accumulated Depreciation, Total | -7.23 | -5.994 | -5.076 | -4.263 | -3.531 |
Total Current Liabilities | 33.154 | 30.022 | 23.296 | 30.245 | 22.58 |
Accounts Payable | 8.68 | 8.146 | 5.076 | 8.668 | 7.881 |
Accrued Expenses | 20.462 | 19.062 | 17.51 | 21.577 | 14.699 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 102.5 | 99.684 | 91.553 | 98.495 | 94.242 |
Total Long Term Debt | 52.934 | 52.859 | 52.785 | 52.711 | 52.636 |
Long Term Debt | 52.934 | 52.859 | 52.785 | 52.711 | 52.636 |
Other Liabilities, Total | 16.412 | 16.803 | 15.472 | 15.539 | 19.026 |
Total Equity | 137.86 | 149.959 | 157.617 | 60.529 | 62.201 |
Redeemable Preferred Stock | 0 | 0 | 0 | ||
Common Stock | 0.062 | 0.062 | 0.061 | 0.055 | 0.046 |
Additional Paid-In Capital | 265.912 | 260.561 | 255.786 | 145.221 | 142.463 |
Retained Earnings (Accumulated Deficit) | -127.966 | -110.445 | -98.174 | -84.72 | -80.308 |
Total Liabilities & Shareholders’ Equity | 240.36 | 249.643 | 249.17 | 159.024 | 156.443 |
Total Common Shares Outstanding | 61.6069 | 61.5284 | 61.2807 | 55.6282 | 55.4992 |
Cash | 4.54 | 2.951 | 3.466 | 3.262 | 2.707 |
Other Long Term Assets, Total | 0.146 | 0.146 | 0.215 | 0.146 | 0.146 |
Short Term Investments | 114.885 | 127.444 | 141.049 | 61.779 | |
Other Equity, Total | -0.148 | -0.219 | -0.056 | -0.027 | |
Other Current Liabilities, Total | 4.012 | 2.814 | 0.71 | ||
Goodwill, Net | 12.815 | 12.815 | |||
Intangibles, Net | 9.262 | 9.5 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | |
---|---|---|---|---|
Net income/Starting Line | -42.815 | -20.552 | -3.668 | -4.265 |
Cash From Operating Activities | -30.648 | -17.193 | -4.494 | -7.673 |
Cash From Operating Activities | 2.133 | 0.685 | 1.21 | 0.793 |
Non-Cash Items | 15.843 | 4.004 | 3.282 | 1.107 |
Cash Interest Paid | 4.398 | 3.9 | 1.146 | 0.739 |
Changes in Working Capital | -5.809 | -1.33 | -5.318 | -5.308 |
Cash From Investing Activities | -76.518 | -2.705 | -1.069 | -1.211 |
Capital Expenditures | -14.838 | -2.705 | -1.069 | -1.211 |
Cash From Financing Activities | 20.806 | 107.652 | 11.503 | 19.739 |
Financing Cash Flow Items | -0.989 | 0 | -0.179 | -0.329 |
Issuance (Retirement) of Stock, Net | 2.187 | 109.44 | 0.364 | 0.068 |
Issuance (Retirement) of Debt, Net | 19.608 | -1.788 | 11.318 | 20 |
Net Change in Cash | -86.36 | 87.754 | 5.94 | 10.855 |
Other Investing Cash Flow Items, Total | -61.68 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -13.454 | -42.815 | -38.403 | -26.27 | -9.036 |
Cash From Operating Activities | -17.259 | -30.648 | -25.29 | -17.807 | -7.241 |
Cash From Operating Activities | 0.924 | 2.133 | 1.216 | 0.757 | 0.334 |
Non-Cash Items | 3.845 | 15.843 | 11.911 | 8.7 | 1.727 |
Cash Interest Paid | 1.285 | 4.398 | 3.087 | 1.897 | 0.951 |
Changes in Working Capital | -8.574 | -5.809 | -0.014 | -0.994 | -0.266 |
Cash From Investing Activities | -80.48 | -76.518 | -12.506 | -6.649 | -1.481 |
Capital Expenditures | -1.478 | -14.838 | -12.506 | -6.649 | -1.481 |
Cash From Financing Activities | 107.879 | 20.806 | 20.509 | 20.156 | 1.372 |
Financing Cash Flow Items | -0.989 | -0.989 | -0.989 | ||
Issuance (Retirement) of Stock, Net | 107.879 | 2.187 | 1.89 | 1.537 | 1.372 |
Issuance (Retirement) of Debt, Net | 19.608 | 19.608 | 19.608 | 0 | |
Net Change in Cash | 10.14 | -86.36 | -17.287 | -4.3 | -7.35 |
Other Investing Cash Flow Items, Total | -79.002 | -61.68 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Treace Medical Concepts, Inc. Company profile
About Treace Medical Concepts Inc
Treace Medical Concepts, Inc. is a commercial-stage orthopaedic medical device company. The Company is focused on strategic product development activities that improve surgical efficiencies and patient outcomes. The Company's proprietary Lapiplasty 3-dimensional (3D) Bunion Correction System, which is a combination of instruments, implants and surgical methods designed to correct all three dimensions of the bunion deformity, address the root cause of the bunion deformity. The Lapiplasty System combines novel surgical approach, the Lapiplasty Procedure, with its procedural instrumentation and single-use implant kits. The Lapiplasty Procedure is designed to rotate the entire metatarsal bone into normal anatomical position in all three dimensions, eliminating the bump and restoring normal anatomy. The Lapiplasty Procedure can be performed in either hospital outpatient or ambulatory surgery center settings. The Company's brands include Lapiplasty, Fast Grafter and Plantar Python.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Treace Medical Concepts Inc revenues increased 65% to $94.4M. Net loss applicable to common stockholders increased from $4.3M to $20.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Sales and marketing - Balancing value increase of 79% to $50.2M (expense).
Industry: | Medical Equipment |
100 Palmetto Park Place
PONTE VEDRA
FLORIDA 32081
US
Income Statement
- Annual
- Quarterly
News
A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024Higher CPI leaves traders unfazed as US equities continue to build momentum
The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.
12:42, 15 March 2024Four reasons why Bitcoin is surging to record highs
Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.
10:18, 14 March 2024China’s National People’s Congress: The markets have again been left wanting more
China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.
08:23, 8 March 2024Central Banks: which one will cut first?
Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut
13:14, 6 March 2024Nvidia (NVDA) confronts high expectations for Q4 results
Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.
12:13, 20 February 2024People also watch
Still looking for a broker you can trust?
Join the 580.000+ traders worldwide that chose to trade with Capital.com